Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain
Not yet recruitingNot applicableNCT07101978
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study, in a quasi-experimental matched two-group pre-post design, investigates the effect of serial water-filtered whole-body hyperthermia on circadian core body temperature, the somatosensory system (nociception) and the movement evoked pain in healthy and patients with chronic primary pain (e.g., fibromyalgia). The intervention lasts 3 weeks with two treatment sessions per week.
Study details
- Official title
- Hyperthermia in Healthy and Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System, Movement Evoked Pain (HYPPRI-1)
- Conditions
- Hyperthermia
- Chronic Primary Pain
- Widespread Pain
- Muscular Disease
- Rheumatic Diseases
- Musculoskeletal Diseases
- Neuromuscular Disease
- Fibromyalgia
- Circadian Rhythm
- Body Temperature Changes
- Somatosensory Function
- Quantitative Sensory Testing
- Healthy
- Interventions
- Behavioral: serial whole body hyperthermia
- Sponsor
- Bern University of Applied Sciences
- Collaborators
- Dr. med. h.c Erwin Braun Stiftung
- Start date
- 2026-12-01
- Primary completion
- 2028-12-30
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Switzerland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: patients: * Confirmed diagnosis of widespread pain (ICD-11 MG30.01) * Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) scale ≥ 5 or WPI) ≥ 3 and SS ≥ 9, * Pain \>= 3 month and VAS \>= 4,0 * Body - infrared-A-Bulb Distance \< 38cm (overweight participants) * Signed declaration of consent healthy: * No chronic illnesses * No acute infections * No regular medication: To avoid interactions * BMI ≤ 40kg/cm2 * Mental health: No psychiatric diagnoses or psychotropic medication in your medical history Exclusion Criteria: * Participation in other clinical studies * Contraindications for hyperthermia (severe cardiovascular diseases, tumour diseases, acute infections, pregnant and breastfeeding women) * Acute and / or feverish microbial infections * Participants with severe somatic, rheumatic concomitant endocrine or neurological diseases, in particular neurological diseases associated with cognitive disorders, severe liver or kidney and cardiac diseases * participants who are permanently treated with opioids, cannabis, immunosuppressive drugs (e.g. corticoids, immunosuppressants) or alpha/beta-A(nta)gonists due to a disease from the group described above * participants with pain due to a serious psychiatric illness (bipolar disorder, psychosis, personality disorder, severe depression, substance abuse) and serious systemic or neurological disorders * pregnancy or breastfeeding (for women) * Intake of medication within 6 weeks that inhibits the reuptake of the neurotransmitter serotonin or binds to receptors of this neurotransmitter group
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07101978